Big Pharma Failure Shows Value of Multifaceted Approach to Cancer Treatment

The Old Is Now New
The Old Is Now New

“Everything old is new again” might be one of the themes of modern cancer research. Repeatedly, cancer researchers in the U.S. and Western Europe are finding validity in many of the “old” methods of treating cancer and embracing them as “new” discoveries. Integrated immunotherapy, which Issels Integrative Oncology Centers have practiced for more than 60 years, is a notable example.

Big Pharma Fails Again

That the body’s own immune system holds the key to defeating cancer is an idea only recently embraced by a Western medical community that many believe relies too heavily on Big Pharma. But as the recent clinical trial failure of yet another cancer drug touted by its maker as “a potential blockbuster” indicates, cancer patients may be placing their lives at risk by failing to broaden their treatment plans to include alternative cancer treatment options.

The Issels Difference

At Issels alternative cancer treatment centers, our experienced cancer specialists take a holistic approach to fighting cancer that treats the patient’s body, mind and spirit. Central to our cancer-fighting strategy are treatments designed to bolster and restore the body’s immune, regulatory and repair mechanisms and enhance their ability to recognize and destroy cancer cells.

Personalized Treatment

We recognize that each patient’s case is unique. Just as cancer is not a single disease, we know from our extensive clinical experience that each patient’s response to cancer and cancer treatment will be unique. Using special testing methods, including genomic testing, our experts personalize the Issels immunobiologic core treatment program to the specific needs of each individual patient.

Rather than limiting cancer treatment to surgery, chemotherapy and radiation as is common among practitioners of Western medicine, Issels integrative immunotherapy, which can be used alone or with traditional treatments, expands cancer treatment, increasing the patient’s opportunities for long-term cancer remission.